Zhejiang Hisun Pharmaceutical Company Overview

  • Year Founded
  • 1956

Year Founded

  • Status
  • Public

  • Employees
  • 8,751

Employees

  • Stock Symbol
  • 600267

Stock Symbol

  • Investments
  • 14

  • Share Price
  • $1.82
  • (As of Friday Closing)

Zhejiang Hisun Pharmaceutical Company General Information

Description

Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Number 46 Waisha Road
  • Jiaojiang District
  • Taizhou, Zhejiang 318000
  • China
+86 0576
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • Number 46 Waisha Road
  • Jiaojiang District
  • Taizhou, Zhejiang 318000
  • China
+86 0576

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zhejiang Hisun Pharmaceutical Company Stock Performance

As of 20-Nov-2026, Zhejiang Hisun Pharmaceutical Company’s stock price is $1.82. Its current market cap is $2.14B with 1.18B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.82 $1.88 $1.37 - $2.22 $2.14B 1.18B 31.6M $0.15

Zhejiang Hisun Pharmaceutical Company Financials Summary

As of 30-Sep-2026, Zhejiang Hisun Pharmaceutical Company has a trailing 12-month revenue of $1.33B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,202,487 1,999,718 1,834,807 2,326,380
Revenue 1,327,149 1,466,996 1,441,057 1,420,883
EBITDA 238,907 260,485 270,003 163,553
Net Income 177,794 75,189 83,783 (13,169)
Total Assets 2,061,602 2,151,239 2,187,981 2,484,733
Total Debt 230,695 439,002 581,314 802,984
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Zhejiang Hisun Pharmaceutical Company Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development
Biotechnology
Taizhou, China
8,751 As of 2025

Basel, Switzerland
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Zhejiang Hisun Pharmaceutical Company Competitors (27)

One of Zhejiang Hisun Pharmaceutical Company’s 27 competitors is Roche, a Corporation company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Roche Corporation Basel, Switzerland
GSK Corporation London, United Kingdom
Teva Pharmaceutical Industries Corporation Tel Aviv, Israel
Biocon Formerly PE-Backed Bengaluru, India
Wockhardt Corporation Mumbai, India
You’re viewing 5 of 27 competitors. Get the full list »

Zhejiang Hisun Pharmaceutical Company Patents

Zhejiang Hisun Pharmaceutical Company Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026223649-A1 Azabicyclic derivative, preparation method therefor and use thereof Pending 21-Apr-2025
WO-2026214668-A1 Azaheterocyclic aminocarboxylate derivative, preparation method therefor, and use thereof Pending 11-Apr-2025
WO-2026208980-A1 Salt of aromatic amide derivative and preparation method therefor and use thereof Pending 03-Apr-2025
WO-2026179869-A1 Substituted aromatic derivative, and preparation method therefor and use thereof Pending 26-Feb-2025
WO-2026179879-A1 Tetrahydropyridazine derivative, and preparation method therefor and use thereof Pending 26-Feb-2025
To view Zhejiang Hisun Pharmaceutical Company’s complete patent history, request access »

Zhejiang Hisun Pharmaceutical Company Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zhejiang Hisun Pharmaceutical Company Investments & Acquisitions (14)

Zhejiang Hisun Pharmaceutical Company’s most recent deal was a PE Growth/Expansion with Sundoc for . The deal was made on 30-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Sundoc 30-Jun-2026 PE Growth/Expansion Drug Discovery
JSIAMA Biopharmaceuticals 26-Mar-2025 Early Stage VC Biotechnology
Fanxi 25-Apr-2024 Later Stage VC Drug Discovery
Angel Pharmaceuticals 06-Oct-2020 Early Stage VC Drug Discovery
Hanhui Pharmaceutical 08-Jul-2020 Secondary Transaction - Private Pharmaceuticals
You’re viewing 5 of 14 investments and acquisitions. Get the full list »

Zhejiang Hisun Pharmaceutical Company ESG

Risk Overview

Risk Rating

Updated March, 31, 2025

40.5 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Pharmaceuticals

Subindustry

of 406

Rank

Percentile

To view Zhejiang Hisun Pharmaceutical Company’s complete esg history, request access »

Zhejiang Hisun Pharmaceutical Company Exits (6)

Zhejiang Hisun Pharmaceutical Company’s most recent exit was on 19-Dec-2017 from DTRM Biopharma. The exit was categorized as with 5 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
DTRM Biopharma 19-Dec-2017 Completed
  • 5 buyers
Photolitec 07-Jan-2016 Completed
IMD Natural Solutions 31-Aug-2015 Completed
Pharmaceutical Industry 08-Oct-2013 Completed
Sagent Pharmaceuticals 01-Aug-2010 Early Stage VC Completed
  • 4 buyers
You’re viewing 5 of 6 exits. Get the full list »

Zhejiang Hisun Pharmaceutical Company Affiliates

Subsidiaries (3)

Name Industry Location Year Founded
Hisun SuliKang Taizhou, China 2015
Hanhui Pharmaceutical Hangzhou, China 2012
Hisun (China) Hangzhou, China 2009

Zhejiang Hisun Pharmaceutical Company FAQs

  • When was Zhejiang Hisun Pharmaceutical Company founded?

    Zhejiang Hisun Pharmaceutical Company was founded in 1956.

  • Where is Zhejiang Hisun Pharmaceutical Company headquartered?

    Zhejiang Hisun Pharmaceutical Company is headquartered in Taizhou, China.

  • What is the size of Zhejiang Hisun Pharmaceutical Company?

    Zhejiang Hisun Pharmaceutical Company has 8,751 total employees.

  • What industry is Zhejiang Hisun Pharmaceutical Company in?

    Zhejiang Hisun Pharmaceutical Company’s primary industry is Biotechnology.

  • Is Zhejiang Hisun Pharmaceutical Company a private or public company?

    Zhejiang Hisun Pharmaceutical Company is a Public company.

  • What is Zhejiang Hisun Pharmaceutical Company’s stock symbol?

    The ticker symbol for Zhejiang Hisun Pharmaceutical Company is 600267.

  • What is the current stock price of Zhejiang Hisun Pharmaceutical Company?

    As of 20-Nov-2026 the stock price of Zhejiang Hisun Pharmaceutical Company is $1.82.

  • What is the current market cap of Zhejiang Hisun Pharmaceutical Company?

    The current market capitalization of Zhejiang Hisun Pharmaceutical Company is $2.14B.

  • What is Zhejiang Hisun Pharmaceutical Company’s current revenue?

    The trailing twelve month revenue for Zhejiang Hisun Pharmaceutical Company is $1.33B.

  • Who are Zhejiang Hisun Pharmaceutical Company’s competitors?

    Roche, GSK, Teva Pharmaceutical Industries, Biocon, and Wockhardt are some of the 27 competitors of Zhejiang Hisun Pharmaceutical Company.

  • What is Zhejiang Hisun Pharmaceutical Company’s annual earnings per share (EPS)?

    Zhejiang Hisun Pharmaceutical Company’s EPS for 12 months was $0.15.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process